<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: We hypothesized that metachronous colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> (CLM) have different biology after failure of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> (FOLFOX) compared to <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> (5-FU) or no chemotherapy for adjuvant treatment of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>BACKGROUND: It is unclear whether patients treated with liver resection for metachronous CLM after adjuvant FOLFOX for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> have worse outcomes than those who received 5-FU or no chemotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We identified 341 patients who underwent hepatectomy for metachronous CLM (disease-free interval ≥12 months, 1993-2010) </plain></SENT>
<SENT sid="3" pm="."><plain>Mass-spectroscopy genotyping for somatic gene mutations in CLM was performed in a subset of 129 patients </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Adjuvant treatment for primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> was FOLFOX in 77 patients, 5-FU in 169 patients, and no chemotherapy in 95 patients </plain></SENT>
<SENT sid="5" pm="."><plain>Node-positive primary was comparable between FOLFOX and 5-FU but lower in the no-chemotherapy group (P &lt; 0.0001) </plain></SENT>
<SENT sid="6" pm="."><plain>Median <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> size was smaller in the FOLFOX group (2.5 cm) than in the 5-FU (3.0 cm) or no-chemotherapy (3.5 cm) groups, (P = 0.008) although prehepatectomy chemotherapy utilization, <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> number, and carcinoembryonic antigen levels were similar </plain></SENT>
<SENT sid="7" pm="."><plain>Disease-free survival (DFS) and overall survival (OS) rates after hepatectomy were worse in patients treated with adjuvant FOLFOX [DFS at 3 years: 14% vs 38% (5-FU) vs 45% (no-chemo), OS at 3 years: 58% vs 70% (5-FU) vs 84% (no-chemo)] </plain></SENT>
<SENT sid="8" pm="."><plain>On multivariate analysis, adjuvant FOLFOX was associated with worse DFS (P &lt; 0.0001) and OS (P &lt; 0.0001) </plain></SENT>
<SENT sid="9" pm="."><plain>Mutation analysis revealed ≥1 mutations in 57% of patients (27/47) after FOLFOX, 29% (12/41) after 5-FU, and 32% (13/41) after no chemotherapy (P = 0.011) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Adjuvant FOLFOX for primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> is associated with a high rate of <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> in <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> and inferior outcomes after hepatectomy for metachronous CLM </plain></SENT>
</text></document>